Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1970 2
1972 2
1977 1
1978 1
1979 2
1980 3
1981 2
1983 5
1984 2
1987 3
1988 3
1989 4
1990 6
1991 10
1992 5
1993 3
1994 3
1995 6
1996 9
1997 10
1998 5
1999 11
2000 16
2001 10
2002 18
2003 9
2004 17
2005 12
2006 16
2007 13
2008 11
2009 11
2010 13
2011 31
2012 24
2013 21
2014 30
2015 15
2016 24
2017 16
2018 25
2019 24
2020 36
2021 29
2022 42
2023 38
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

556 results

Results by year

Filters applied: . Clear all
Page 1
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T. Nakamura Y, et al. Among authors: kawamoto y. Nat Med. 2020 Dec;26(12):1859-1864. doi: 10.1038/s41591-020-1063-5. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020649 Clinical Trial.
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Ohba A, et al. Among authors: kawamoto y. Future Oncol. 2022 Jun;18(19):2351-2360. doi: 10.2217/fon-2022-0214. Epub 2022 May 5. Future Oncol. 2022. PMID: 35510484 Free article.
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: kawamoto y. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C. Umemoto K, et al. Among authors: kawamoto y. Br J Cancer. 2023 Apr;128(8):1603-1608. doi: 10.1038/s41416-023-02189-y. Epub 2023 Feb 13. Br J Cancer. 2023. PMID: 36782009 Free PMC article.
Total Synthesis of Asperaculin A.
Kobayashi T, Teshigahara Y, Sakakibara M, Murakami K, Kawamoto Y, Ito H. Kobayashi T, et al. Among authors: kawamoto y. Org Lett. 2023 Jun 23;25(24):4510-4513. doi: 10.1021/acs.orglett.3c01530. Epub 2023 Jun 13. Org Lett. 2023. PMID: 37310079
Total synthesis of applanatumol A.
Uchida K, Kawamoto Y, Kobayashi T, Ito H. Uchida K, et al. Among authors: kawamoto y. Chem Commun (Camb). 2023 Jun 27;59(52):8139-8142. doi: 10.1039/d3cc01997g. Chem Commun (Camb). 2023. PMID: 37309641
Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.
Arai A, Yoshimitsu M, Otsuka M, Ito Y, Miyazono T, Nakano N, Obama K, Nakashima H, Hanada S, Owatari S, Nakamura D, Tokunaga M, Kamada Y, Utsunomiya A, Haraguchi K, Hayashida M, Fujino S, Odawara J, Tabuchi T, Suzuki S, Hamada H, Kawamoto Y, Uchida Y, Hachiman M, Ishitsuka K. Arai A, et al. Among authors: kawamoto y. Eur J Haematol. 2023 Jun;110(6):639-647. doi: 10.1111/ejh.13945. Epub 2023 Mar 14. Eur J Haematol. 2023. PMID: 36811253
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Takada R, Ikezawa K, Yamai T, Watsuji K, Seiki Y, Kawamoto Y, Hirao T, Higashi S, Urabe M, Kai Y, Nakabori T, Uehara H, Kotani M, Yagi T, Kimura M, Nozaki K, Takagi M, Ohkawa K. Takada R, et al. Among authors: kawamoto y. BMC Cancer. 2023 Jul 31;23(1):711. doi: 10.1186/s12885-023-11205-6. BMC Cancer. 2023. PMID: 37518012 Free PMC article.
556 results